IL-6: A magic potion for liver transplantation?

Gastroenterology

Volumn 125, Issue 1, 2003, Pages 256-259

  Selzner, Markus ^a   Graf, Rolf ^a   Clavien, Pierre Alain ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYTOKINE; INTERLEUKIN 6; PROTEIN BCL 2; PROTEIN BCL XL; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADULT; AGED; ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; CELL DEATH; CELL PROTECTION; EDITORIAL; FATTY LIVER; HUMAN; INTESTINE CELL; KNOCKOUT MOUSE; LIVER BIOPSY; LIVER CELL; LIVER DISEASE; LIVER TRANSPLANTATION; MOUSE; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RISK FACTOR;

EID: 0038054086     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(03)00811-4     Document Type: Editorial

References (42)

1. Marsmann W, Wiesner R, Rodriguez L, Batts K, Porayko M, Hay J, Gores G, Krom R. Use of fatty donor liver is associated with diminished early patient and graft survival. Transplantation 1996; 62:1246-1251.
2. Strasberg S, Howard T, Molmenti E, Hert M. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology 1994;20:829-838.
3. Todo S, Demetris A, Teperman L, Podesta L, Shaver T, Tzakis A, Starzl T. Primary nonfunction of hepatic allografts with preexisting fatty infiltration. Transplantation 1989;47:903-905.
4. D'Alessandro A, Kalayoglu M, Sollinger H, Hoffmann R, Reed A, Knechtle S, Pirsch J, Hafez G, Lorentzen D, Belzer F. The predictive value of donor liver biopsies for the development of primary nonfunction after orthotopic liver transplantation. Transplantation 1991;51:157-163.
5. Adam R, Reynes M, Johann M, Morino M, Astarcioglu I, Kafetzis I, Castaing D, Bismuth H. The outcome of steatotic grafts in liver transplantation. Transpl Proc 1991;23:1538-1540.
6. Markin RS, Wisecarver JL, Radio SJ, Stratta RJ, Langnas AN, Hirst K, Shaw BW Jr. Frozen section evaluation of donor livers before transplantation. Transplantation 1993;56:1403-1409.
7. Hilden M, Christoffersen P, Juhl E, Dalgaard J. Liver histology in a normal population-examinatons of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 1977;12:593-597.
8. Underwood G. Prevalence of fatty liver in healthy male adults accidentally killed. Aviat Space Environ Med 1984;55:59-63.
9. Selzner M, Clavien PA. Fatty liver in transplantation and surgery. Sem Liver Dis 2001;21:105-113.
10. Fishbein T, Fiel M, Emre S, Cubukcu O, Guy S, Schwartz M, Miller C, Sheiner P. Use of livers with microvesicular fat safely expands the donor pool. Transplantation 1997;64:248-251.
11. Seizner M, Rüdiger H, Sindram D, Madden J, Clavien PA. Mechanisms of ischemic injury are different in the steatotic and normal rat liver. Hepatology 2000;32:1280-1288.
12. Seizner M, Camargo C, Clavien PA. Ischemia impairs liver regeneration following major tissue loss in the rodent. Hepatology 1999;30:469-475.
13. Yang S, Lin H, Mandal A, Huang J, Diehl A. Disrupted signaling and inhibited regeneration in obese mice with fatty livers: implication for nonalcoholic fatty liver disease pathophysiology. Hepatology 2001;34:694-706.
14. Seizner M, Clavien P-A. Failure of regeneration of the steatotic rat liver: disruption at two different levels of the regeneration pathway. Hepatology 2000;31:35-42.
15. Urena M, Ruiz-Delgado F, Gonzales E, Segurola C, Romero C, Garcia I, Gonzales-Pinto I, Gomez Sanz R. Assessing risk of the use of livers with macro and microsteatosis in a liver transplant program. Transpl Proc 1998;30:3288-3291.
16. Urena M, Ruiz-Delgado F, Gonzales E, Romero C, Garcia I, Segurola C, Gonzales-Pinto I, Sanz R. Hepatic steatosis in liver transplant donors: common feature of donor population? World J Surg 1998;22:837-844.
17. Yoong K, Gunson B, Nell D, Mirza D, Mayer A, Buckels J, McMaster P. Impact of donor liver microvesicular steatosis on the outcome of liver retransplantation. Transplant Proc 1999;31:550-551.
18. Busquets J, Figueras J, Serrano T, Torras J, Ramos E, Rafecas A, Fabregat J, Lama C, Xiol X, Baliellas C, Jaurrieta E. Postreperfusion biopsies are useful in predicting complications after liver transplantation. Liver Transpl 2001;7:432-435.
19. Briceno J, Marchal T, Padillo J, Solorzano G, Pera C. Influence of marginal donors on liver preservation injury. Transplantation 2002;74:522-526.
20. Sun Z, Klein AS, Radaeva S, Hong F, El-Assal O, Pan H-N, Jaruga B, Batkai S, Hoshino S, Tian Z, Kunos G, Diehl AM, Gao B. In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats. Gastroenterology 2003;125:202-215.
21. Koteish A, Diehl A. Animal models of steatosis. Semin Liver Dis 2001;21:98-104.
22. Lemasters J. Necrapoptosis and the mitochondrial permeability transition: shared pathways to necrosis and apoptosis. Am J Physiol 1999;276:G1-G6.
23. Clavien PA, Camargo CA, Gorczynski R, Washington MK, Levy GA, Langer B, Greig PD. Acute reactant cytokines and neutrophil adhesion after warm ischemia in cirrhotic and noncirrhotic human livers. Hepatology 1996;23:1456-1463.
24. Cressman DE, Greenbaum LE, DeAngelis RA, Ciliberto G, Furth EE, Poli V, Taub R. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996;274: 1379-1383.
25. Camargo CA Jr, Madden JF, Gao W, Selvan RS, Clavien PA. Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent. Hepatology 1997;26:1513-1520.
26. Yamada Y, Kirillova I, Peschon JJ, Fausto N. Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc Natl Acad Sci U S A 1997;94:1441-1446.
27. Sakamoto T, Liu Z, Murase N, Ezure T, Yokomuro S, Poli V, Demetris A. Mitosis and apoptosis in the liver of interleukin-6-deficient mice after partial hepatectomy. Hepatology 1999;29: 403-411.
28. Seizner N, Seizner M, Odermatt B, Tian Y, Rooijin N, Clavien PA. ICAM-1 triggers liver regeneration through TNF and IL-6 release in mice. Gastroenterology 2003;124:692-700.
29. Hong F, Kim W, Tian Z, Jaruga B, Ishac E, Shen X, Gao B. Elevated interleukin-6 during ethanol consumption acts as a potential endogenous protective cytokine against ethanol-induced apoptosis in the liver: involvement of induction of Bcl-2 and Bcl-xL proteins. Oncogene 2002;21:32-43.
30. Kovalovich K, Li W, DeAngelis R, Greenbaum L, Ciliberto G, Taub R. Interleukin-6 protects against Fas-mediated death by establishing a critical level of anti-apoptotic hepatic proteins FLIP, Bcl-2, and Bcl-xL. J Biol Chem 2001;276:26605-26613.
31. Veldhuis G, Willemse P, Mulder N, Limburg P, De Vries E. Potential use of recombinant human interleukin-6 in clinical oncology. Leuk Lymphoma 1996;20:673-679.
32. Tate J, Olencki T, Finke J, Kottke-Marchant K, Rybicki L, Bukowski R. Phase I trial of simultaneously administration of GM-CSF and IL-6 in patients with renal cell carcinoma: clinical and laboratory effects. Ann Oncol 2001;12:655-659.
33. Gao W, Bentley RC, Madden JF, Clavien PA. Apoptosis of sinusoidal endothelial cells is a critical mechanism of prevention injury in rat liver transplantation. Hepatology 1998;27:1652-1660.
34. Natori S, Seizner M, Valentino K, Fritz L, Srinivasan A, Clavien P-A, Gores G. Apoptosis of sinusoidal endothelial cells occurs during liver preservation injury by a caspase-dependent mechanism. Transplantation 1999;68:89-96.
35. Seizner N, Rudiger H, Graf R, Clavien PA. Protective strategies against ischemic injury of the liver. Gastroenterology 2003;in press.
36. Sun X, Kimura T, Kobayashi T, Noriki S, Imamura Y, Fukuda M, Yamaguchi A. Viability of liver grafts from fated donor rats: relationship to sinusoidal endothelial cell apoptosis. J Hepatobiliary Pancreat Surg 2001;8:268-273.
37. Matsumoto K, Honda K, Kobayashi N. Protective effect of heat preconditioning of rat liver graft resulting in improved transplant survival. Transplantation 2001;71:862-868.
38. Seifalian A, Piasecki C, Agarwal A, Davidson B. The effect of graded steatosis on flow in the hepatic parenchymal microcirculation. Transplantation 1999;68:780-784.
39. Serafin A, Rosello-Catafau J, Prats N, Xaus C, Gelpi E, Peralta C. Ischemic preconditioning increases the tolerance of fatty liver to hepatic ischemia-reperfusion injury in the rat. Am J Pathol 2002; 161:587-601.
40. Seizner N, Seizner M, Jochum W, Clavien PA. Ischemic preconditioning protects the steatotic mouse liver against reperfusion injury: an ATP dependent mechanism. J Hepatol 2003;in press.
41. Peralta C, Bartrons R, Riera L, Manzano A, Xaus C, Gelpi E, Rosello-Catafau J. Hepatic preconditioning preserves energy metabolism during sustained ischemia. Am J Physiol 2000;279: G163-G171.
42. Fukushima K, Sasaki I, Takahashi K, Naito H, Matsuno S. Lipopolysaccharide and proinflammatory cytokine-induced energy production in intestinal and colonic epithelial cell lines. Scand J Gastroenterol 1999;34:291-296.